Middle East tender deferral persists
Tender-based supplies to the Middle East remain on hold due to geopolitical tensions, with no clear timeline for resumption.
medium · management_commentaryConcord Biotech Limited — Q3 FY26
Concord Biotech reported Q3 FY26 revenue of ₹278 crore, up 14% YoY, driven by API growth of 24% to ₹219 crore.
neutral
medium
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Injectable ramp-up slower than expected
The injectable facility is still in early stages; revenue contribution was insignificant in Q3, and scaling up may take longer than anticipated.
medium · data_observationUS tariff uncertainty for new products
While tariffs do not apply to already-launched generics, new product launches could be impacted if tariff policies change, as noted in analyst Q&A.
medium · analyst_question